Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539696 | 0.92 | PPARD (0.47) | PPARDMTNR1AMTNR1BNR4A2NR4A1 | |
| SCHEMBL6539706 | 0.90 | HDAC8 (0.44) | PPARDHDAC8NR4A2NR4A1NR4A3 | |
| SCHEMBL6539197 | 0.89 | PPARD (0.46) | PPARDHDAC8NR4A2NR4A1NR4A3 | |
| SCHEMBL6538965 | 0.88 | HDAC8 (0.45) | PPARDMTNR1AMTNR1BHDAC8NPC1 | |
| SCHEMBL6540089 | 0.87 | PPARD (0.41) | PPARDMTNR1AMTNR1BHDAC8NR4A2 | |
| SCHEMBL6539587 | 0.85 | PPARD (0.44) | PPARDMTNR1AMTNR1BNR4A2 | |
| SCHEMBL6539575 | 0.84 | PPARD (0.48) | PPARDHDAC8NR4A2NR4A1NR4A3 | |
| SCHEMBL6539566 | 0.84 | PPARD (0.41) | PPARDHDAC8NR4A2NR4A1NR4A3 | |
| SCHEMBL6538996 | 0.84 | MTNR1A (0.48) | PPARDMTNR1AMTNR1BHDAC8GSK3B | |
| SCHEMBL6539856 | 0.82 | MTNR1A (0.48) | PPARDMTNR1AMTNR1BHDAC8GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885MTNR1A 410/4885MTNR1B 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.